Do analysts prefer LFVN or ALVR?

Lifevantage currently has a consensus price target of $5.00, suggesting a potential downside of 23.43%. Given Lifevantage's stronger consensus rating and higher probable upside, equities analysts plainly believe Lifevantage is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, LFVN or ALVR?

Lifevantage has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifevantage $228.53M 0.36 $9.81M $0.45 14.51 AlloVir N/A N/A -$190.42M -$20.23 N/A

Is LFVN or ALVR more profitable?

Lifevantage has a net margin of 2.94% compared to AlloVir's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Lifevantage 2.94% 23.89% 12.47% AlloVir N/A -71.03% -61.27%

Do analysts prefer ALVR or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, ALVR or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is ALVR or TELO more profitable?

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Telomir Pharmaceuticals N/A -201.23% -172.71%

Which has preferable valuation & earnings, ENLV or ALVR?

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is ENLV or ALVR more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% AlloVir N/A -71.03% -61.27%

Do analysts prefer GANX or ALVR?

Gain Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gain Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, GANX or ALVR?

Gain Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is GANX or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% AlloVir N/A -71.03% -61.27%

Do analysts prefer SPRO or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

AlloVir (ALVR) Competitors

$3.73 -0.19 (-4.85%)

As of 07/24/2026

Compare

ALVR vs. LFVN, TELO, ENLV, GANX, and SPRO

Should you buy AlloVir stock or one of its competitors? MarketBeat compares AlloVir with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AlloVir include Lifevantage (LFVN), Telomir Pharmaceuticals (TELO), Enlivex Therapeutics (ENLV), Gain Therapeutics (GANX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

How does AlloVir compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Lifevantage currently has a consensus price target of $5.00, suggesting a potential downside of 23.43%. Given Lifevantage's stronger consensus rating and higher probable upside, equities analysts plainly believe Lifevantage is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lifevantage has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Lifevantage has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.36	$9.81M	$0.45	14.51
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Lifevantage has a net margin of 2.94% compared to AlloVir's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
AlloVir	N/A	-71.03%	-61.27%

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lifevantage had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for AlloVir. Lifevantage's average media sentiment score of 1.47 beat AlloVir's score of 0.00 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Positive
AlloVir	Neutral

Summary

Lifevantage beats AlloVir on 12 of the 14 factors compared between the two stocks.

How does AlloVir compare to Telomir Pharmaceuticals?

AlloVir (NASDAQ:ALVR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

In the previous week, Telomir Pharmaceuticals had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 0 mentions for AlloVir. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat AlloVir's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Telomir Pharmaceuticals	Positive

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AlloVir and Telomir Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does AlloVir compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Enlivex Therapeutics currently has a consensus price target of $247.50, indicating a potential upside of 5,792.86%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Enlivex Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Enlivex Therapeutics' return on equity of 248.08% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, Enlivex Therapeutics had 8 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for Enlivex Therapeutics and 0 mentions for AlloVir. Enlivex Therapeutics' average media sentiment score of 0.78 beat AlloVir's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
AlloVir	Neutral

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Enlivex Therapeutics beats AlloVir on 11 of the 14 factors compared between the two stocks.

How does AlloVir compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

AlloVir's return on equity of -71.03% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, Gain Therapeutics had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Gain Therapeutics and 0 mentions for AlloVir. Gain Therapeutics' average media sentiment score of 1.15 beat AlloVir's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gain Therapeutics	Positive
AlloVir	Neutral

Gain Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gain Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gain Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gain Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Summary

Gain Therapeutics beats AlloVir on 7 of the 13 factors compared between the two stocks.

How does AlloVir compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Spero Therapeutics had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Spero Therapeutics and 0 mentions for AlloVir. Spero Therapeutics' average media sentiment score of 0.93 beat AlloVir's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Positive
AlloVir	Neutral

Spero Therapeutics has a net margin of 24.90% compared to AlloVir's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
AlloVir	N/A	-71.03%	-61.27%

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.03	$8.57M	$0.24	4.96
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

Spero Therapeutics beats AlloVir on 11 of the 13 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.81M	$356.09M	$6.87B	$12.26B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	-0.18	N/A	27.11	23.64
Price / Sales	N/A	228.84	517.09	89.57
Price / Cash	N/A	22.44	50.54	59.64
Price / Book	0.13	4.88	10.28	6.07
Net Income	-$190.42M	-$141.03M	$3.60B	$331.99M
7 Day Performance	-14.84%	-1.69%	-1.27%	-0.63%
1 Month Performance	-15.23%	0.21%	-0.37%	-2.00%
1 Year Performance	31.34%	39.82%	18.30%	13.62%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$3.73 -4.8%	N/A	+46.9%	$18.81M	N/A	N/A	110	High Trading Volume
LFVN Lifevantage	2.7357 of 5 stars	$6.28 -1.9%	$5.00 -20.4%	-53.3%	$79.25M	$228.53M	13.96	260	Positive News Gap Down
TELO Telomir Pharmaceuticals	0.4518 of 5 stars	$1.15 +6.0%	N/A	-49.8%	$78.75M	N/A	N/A	1
ENLV Enlivex Therapeutics	3.2006 of 5 stars	$4.60 -2.7%	$247.50 +5,280.4%	-75.5%	$77.85M	N/A	N/A	70	News Coverage Analyst Upgrade Short Interest Decrease
GANX Gain Therapeutics	2.9102 of 5 stars	$1.83 -0.8%	$7.50 +311.0%	+4.2%	$77.84M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. LFVN, TELO, ENLV, GANX, and SPRO

How does AlloVir compare to Lifevantage?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Summary

How does AlloVir compare to Enlivex Therapeutics?

Summary

How does AlloVir compare to Gain Therapeutics?

Summary

How does AlloVir compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. LFVN, TELO, ENLV, GANX, and SPRO

How does AlloVir compare to Lifevantage?

Do analysts prefer LFVN or ALVR?

Which has more volatility and risk, LFVN or ALVR?

Which has better earnings & valuation, LFVN or ALVR?

Is LFVN or ALVR more profitable?

Do insiders & institutionals have more ownership in LFVN or ALVR?

Does the media favor LFVN or ALVR?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Which has more volatility & risk, ALVR or TELO?

Do analysts prefer ALVR or TELO?

Which has preferable earnings & valuation, ALVR or TELO?

Is ALVR or TELO more profitable?

Does the media refer more to ALVR or TELO?

Do institutionals & insiders believe in ALVR or TELO?

Summary

How does AlloVir compare to Enlivex Therapeutics?

Do analysts prefer ENLV or ALVR?

Which has more volatility & risk, ENLV or ALVR?

Is ENLV or ALVR more profitable?

Does the media favor ENLV or ALVR?

Which has preferable valuation & earnings, ENLV or ALVR?

Do insiders and institutionals hold more shares of ENLV or ALVR?

Summary

How does AlloVir compare to Gain Therapeutics?

Is GANX or ALVR more profitable?

Does the media favor GANX or ALVR?

Which has stronger valuation and earnings, GANX or ALVR?

Do insiders & institutionals hold more shares of GANX or ALVR?

Do analysts prefer GANX or ALVR?

Which has more risk and volatility, GANX or ALVR?

Summary

How does AlloVir compare to Spero Therapeutics?

Do analysts prefer SPRO or ALVR?

Does the media favor SPRO or ALVR?

Is SPRO or ALVR more profitable?

Do institutionals and insiders hold more shares of SPRO or ALVR?

Which has more volatility and risk, SPRO or ALVR?

Which has better earnings & valuation, SPRO or ALVR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools